Alcidion Group Ltd Achieves Dual Regulatory Approval for AI-Powered Clinical Documentation Tool
Alcidion Group Ltd (ASX: ALC) has secured dual regulatory registration for its Miya Precision Concept Detection capability, both in Australia and the United Kingdom. Registered as a Class I Software as a Medical Device (SaMD) on the Australian Register of Therapeutic Goods (ARTG #522634) and with the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), this milestone enables Alcidion to commercially deploy the AI-assisted tool as a certified clinical product in its two largest markets.
The Concept Detection feature, part of Alcidion’s Miya Precision platform, helps clinicians by analyzing free-text notes and suggesting standardized medical codes, enhancing documentation and workflow efficiency. With increasing demand for certified medical software in healthcare, this development positions Alcidion for new sales opportunities and strengthens its competitive edge. The company seeks to enhance its offerings for current customers while also attracting new ones, aligning with its goal to drive innovation in healthcare technology.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Alcidion Group Ltd Achieves Dual Regulatory Approval for AI-Powered Clinical Documentation Tool
Alcidion Group Ltd (ASX: ALC) has secured dual regulatory registration for its Miya Precision Concept Detection capability, both in Australia and the United Kingdom. Registered as a Class I Software as a Medical Device (SaMD) on the Australian Register of Therapeutic Goods (ARTG #522634) and with the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), this milestone enables Alcidion to commercially deploy the AI-assisted tool as a certified clinical product in its two largest markets.
The Concept Detection feature, part of Alcidion’s Miya Precision platform, helps clinicians by analyzing free-text notes and suggesting standardized medical codes, enhancing documentation and workflow efficiency. With increasing demand for certified medical software in healthcare, this development positions Alcidion for new sales opportunities and strengthens its competitive edge. The company seeks to enhance its offerings for current customers while also attracting new ones, aligning with its goal to drive innovation in healthcare technology.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au